PLoS ONEMicrobiologyPeer-reviewed journal article
Patterns of compensatory mutations in rpoA/B/C genes of multidrug resistant M. tuberculosis in Uganda
David Patrick KateeteiD, Shakira Namakula, Edgar KigoziiD, Fred Ashaba Katabazi, George William KasuleiD, Kenneth Musisi, Edward Wampande, Deus LukoyeiD, Moses Lutaakome JolobaiD
Abstract
Mutations in rpoB, a gene that encodes the bacterial RNA polymerase (RNAP) beta-subunit, can cause high-level resistance to rifampicin. Approximately 95% of rifampicin-resistant Mycobacterium tuberculosis clinical isolates possess mutations in an 81-base pair rpoB region referred to as the rifampicin-resistance determining region (rpoB/RRDR). Also, rifampicin-resistant M. tuberculosis clinical isolates carry multiple mutations in RNAP genes (i.e., rpoA, rpoB, rpoC, rpoD), particularly rpoA and rpoC, which encode the alpha-(2) and beta'-({beta}') subunits, respectively. Such secondary mutations offset the fitness cost associated with rifampicin-resistance mutations in M. tuberculosis, resulting in resistant strains that are as fit as the wildtype drug-susceptible strains. To analyse the patterns of compensatory mutations in RNAP encoding genes of rifampicin-resistant M. tuberculosis clinical isolates in Uganda, whole genome sequencing and Sanger DNA sequencing were performed on 52 M. tuberculosis clinical isolates - 20 drug-susceptible and 32 multidrug resistant (MDR). A total of 24 (75%) MDR-TB isolates had high-level rifampicin-resistance conferring mutations in rpoB/RRDR i.e., Ser531Leu (31%); His526Asp (6%); His526Leu (3%); His526Tyr (3%); His526Arg (3%); His526Gly (3%); Asp516Tyr (13%); Asp516Val (6%); Glu513Lys (3%); Leu511Pro (3%); Leu492Leu (3%); Gln490Arg (3%). Further, two putative compensatory mutations (Gln490Arg & Lys1025Glu) outside the RRDR and not resistance conferring were found in rpoB. Altogether, 16 (50%) MDR-TB isolates with rpoB/RRDR resistance conferring mutations had non-synonymous mutations in rpoC of the following patterns Leu39Phe (3%); Tyr61His (3%); Asp271Gly (3%); Ser377Ala (3%); Pro481Thr (3%); Val483Ala (6%); Leu516Pro (3%); Ala521Asp (3%); Gly594Glu (13%); Asn698Ser (3%); Leu823Pro (3%). In conclusion, putative compensatory mutations are prevalent in rifampicin-resistant M. tuberculosis clinical isolates in Uganda, with rpoC/Gly594Glu and rpoC/Val483Ala as the most frequent. Further studies will determine their association with strain genetic background, fitness and transmission in an endemic setting with a high burden of HIV-TB coinfection.
- organism: human
- assay: whole-genome sequencing
- research focus: cell type annotation
- approach: experimental assay
- Citations
- 2
- FWCI
- 1.54
- Field percentile
- top 16%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Novel and Reported Compensatory Mutations in rpoABC Associate Specifically with Predominant Mycobacterium tuberculosis Rifampicin Resistance Marker rpoB:S450L
D. Conkle-Gutierrez, S. M. Ramirez-Busby, … F. Valafar·bioRxiv·Feb 22, 2022
- Rifampicin and rifabutin resistance in 1000 Mycobacterium tuberculosis clinical isolates
M. R. Farhat, J. Sixsmith, … M. Murray·bioRxiv·Sep 25, 2018
- Association between the rifampicin resistance mutations and rifabutin susceptibility in Mycobacterium tuberculosis: a meta-analysis
- Discordance in Genotypic and Phenotypic anti-tuberculosis drug susceptibility results: time to reconsider critical concentration.
Arti Shrivas, Sarman Singh, … Shashank Purwar·Microbiology SpectrumPeer-reviewed·Feb 4, 2025
- Genome wide analyses reveal the role of mutator phenotypes in the emergence of drug resistance in Mycobacterium tuberculosis
Rima Zein-Eddine, Adrien Le Meur, … Hannu Myllykallio·npj Antimicrobials and ResistancePeer-reviewed·Apr 29, 2025
- Xpert Ultra can unambiguously identify specific rifampicin resistance-conferring mutations
K. C. S. Ng, A. van Deun, … B. C. de Jong·bioRxiv·May 9, 2018